Please login to the form below

Not currently logged in
Email:
Password:

Barry Labinger joins Biothera Pharmaceutical

Brings experience from Human Genome Sciences and 3M Pharmaceuticals
Biothera Pharmaceutical Barry Labinger

US biotech company Biothera Pharmaceutical has appointed Barry Labinger as its new chief executive officer.

Labinger has nearly three decades of pharmaceutical and biotech industry experience, with roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals and Immunex.

His experience with oncology drug development will be particularly useful to the Minnesota-based firm, which is developing a novel cancer immunotherapy.

Richard Mueller, chairman of the board at Biothera Holding Corp, said: “Barry has strong leadership and management skills to take Biothera Pharmaceutical forward and realise the full potential of Imprime PGG, the company's first-in-class immune modulator, which we believe is the next step in immune oncology.

“We are delighted to have such an accomplished executive lead the company through the next phase of its development.”

Labinger most recently served as executive vice president and president, Biosciences Division, at Emergent BioSolutions Inc., where he was responsible for all aspects of product development, manufacturing, and commercialisation.

14th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics